Seminars in oncology最新文献_第7页

Advancements and implications of artificial intelligence for early detection, diagnosis and tailored treatment of cancer 人工智能在癌症早期检测、诊断和量身定制治疗方面的进展和意义

IF 3 3区医学

Seminars in oncology Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1016/j.seminoncol.2025.152349

Sonia Chadha, Sayali Mukherjee, Somali Sanyal

{"title":"Advancements and implications of artificial intelligence for early detection, diagnosis and tailored treatment of cancer","authors":"Sonia Chadha, Sayali Mukherjee, Somali Sanyal","doi":"10.1016/j.seminoncol.2025.152349","DOIUrl":"10.1016/j.seminoncol.2025.152349","url":null,"abstract":"<div><div>The complexity and heterogeneity of cancer makes early detection and effective treatment crucial to enhance patient survival and quality of life. The intrinsic creative ability of artificial intelligence (AI) offers improvements in patient screening, diagnosis, and individualized care. Advanced technologies, like computer vision, machine learning, deep learning, and natural language processing, can analyze large datasets and identify patterns that permit early cancer detection, diagnosis, management and incorporation of conclusive treatment plans, ensuring improved quality of life for patients by personalizing care and minimizing unnecessary interventions. Genomics, transcriptomics and proteomics data can be combined with AI algorithms to unveil an extensive overview of cancer biology, assisting in its detailed understanding and will help in identifying new drug targets and developing effective therapies. This can also help to identify personalized molecular signatures which can facilitate tailored interventions addressing the unique aspects of each patient. AI-driven transcriptomics, proteomics, and genomes represents a revolutionary strategy to improve patient outcome by offering precise diagnosis and tailored therapy. The inclusion of AI in oncology may boost efficiency, reduce errors, and save costs, but it cannot take the role of medical professionals. While clinicians and doctors have the final say in all matters, it might serve as their faithful assistant</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 3","pages":"Article 152349"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dual effect of interferon-γ in acute myeloid leukemia: A narrative review 干扰素-γ在急性髓系白血病中的双重作用：综述

IF 3 3区医学

Seminars in oncology Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1016/j.seminoncol.2025.152347

Abiy Ayele Angelo , Gashaw Adane , Dereje Mengesha Berta , Elias Chane , Negesse Cherie , Mebratu Tamir , Bisrat Birke Teketelew

{"title":"The dual effect of interferon-γ in acute myeloid leukemia: A narrative review","authors":"Abiy Ayele Angelo , Gashaw Adane , Dereje Mengesha Berta , Elias Chane , Negesse Cherie , Mebratu Tamir , Bisrat Birke Teketelew","doi":"10.1016/j.seminoncol.2025.152347","DOIUrl":"10.1016/j.seminoncol.2025.152347","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) is a hematological malignancy representing a very rapid, uncontrolled growth of myeloid precursors in the BM and peripheral circulation. Studies on AML have highlighted the crucial role of IFN-γ therapy in immune surveillance, both promotive and inhibitory effects on leukemic cells, and regulation of the tumor microenvironment. However, there is a need for a comprehensive understanding of the dual effects of IFN-γ in AML. Thus, this review aimed to assess the dual effects of IFN-γ in AML. Literature searches were conducted in Pub Med, Google Scholar, and direct Google Search. The data was presented in tables and figures, with findings summarized through a narrative synthesis. Depending on the circumstances and stage of the disease IFN-γ shows two different activities in AML patients. First, IFN-γ enhances NK cells and CD8<sup>+</sup> <em>T</em> lymphocyte functions, which collectively evoke antileukemic immunity. Another promising effect of IFN-γ includes the differentiation of myeloid cells, thereby possibly reducing the severity of leukemia. However, prolonged exposure to IFN-γ can activate Treg cells and inhibitory immunological checkpoints, which can help leukemia evade immune surveillance and encounter an immunosuppressive environment. Our review highlights IFN-γ's critical role in the complex interplay between the immune system and AML pathogenesis. Its dual role in both inhibiting and promoting leukemic processes has been highlighted. However, future pre-clinical and clinical studies should focus on the specific mechanisms by which IFN-γ impacts AML progression and treatment outcomes, with the goal of achieving curative results for patients.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 3","pages":"Article 152347"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Divergent functions of TLRs in gastrointestinal (GI) cancer: Overview of their diagnostic, prognostic and therapeutic value tlr在胃肠道（GI）肿瘤中的不同功能：其诊断、预后和治疗价值综述

IF 3 3区医学

Seminars in oncology Pub Date : 2025-06-01 Epub Date: 2025-05-09 DOI: 10.1016/j.seminoncol.2025.152344

Chou-Yi Hsu , Saade Abdalkareem Jasim , Khetam Habeeb Rasool , Malathi H , Jaswinder Kaur , Majid S. Jabir , Sharif Alhajlah , Abhinav Kumar , Sabrean F. Jawad , Beneen Husseen

{"title":"Divergent functions of TLRs in gastrointestinal (GI) cancer: Overview of their diagnostic, prognostic and therapeutic value","authors":"Chou-Yi Hsu , Saade Abdalkareem Jasim , Khetam Habeeb Rasool , Malathi H , Jaswinder Kaur , Majid S. Jabir , Sharif Alhajlah , Abhinav Kumar , Sabrean F. Jawad , Beneen Husseen","doi":"10.1016/j.seminoncol.2025.152344","DOIUrl":"10.1016/j.seminoncol.2025.152344","url":null,"abstract":"<div><div>The relationship between the innate immune signal and the start of the adaptive immune response is the central idea of this theory. By controlling the inflammatory and tissue-repair reactions to damage, the Toll-like receptors (TLRs), as a family of PRRs, have attracted increasing attention for its function in protecting the host against infection and preserving tissue homeostasis. Microbial infection, damage, inflammation, and tissue healing have all been linked to the development of malignancies, especially gastrointestinal (GI) cancers. Recently, increased studies on TLR recognition and binding, as well as their ligands, have significantly advanced our knowledge of the various TLR signaling pathways and offered therapy options for GI malignancies. Upon activation by pathogen-associated or damage-associated molecular patterns (DAMPs and PAMPs), TLRs trigger key pathways like NF-κB, MAPK, and IRF. NF-κB activation promotes inflammation, cell survival, and proliferation, often contributing to tumor growth, metastasis, and therapy resistance. MAPK pathways similarly drive uncontrolled cell growth and invasion, while IRF pathways modulate interferon production, yielding both anti-tumor and protumor effects. The resulting chronic inflammatory environment within tumors can foster progression, yet TLR activation can also stimulate beneficial anti-tumor immune responses. However, the functions of TLR expression in GI cancers and their diagnostic and prognostic along with therapeutic value have not yet entirely been elucidated. Understanding how TLR activation contributes to anti-cancer immunity against GI malignancies may hasten immunotherapy developments and increase patient survival.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 3","pages":"Article 152344"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances and challenges in cancer immunotherapy: Strategies for personalized treatment 癌症免疫治疗的进展与挑战：个性化治疗策略

IF 3 3区医学

Seminars in oncology Pub Date : 2025-06-01 Epub Date: 2025-04-29 DOI: 10.1016/j.seminoncol.2025.152345

Mahir Azmal, Md. Munna Miah, Fatema Sultana Prima, Jibon Kumar Paul, ANM Shah Newaz Been Haque, Ajit Ghosh

{"title":"Advances and challenges in cancer immunotherapy: Strategies for personalized treatment","authors":"Mahir Azmal, Md. Munna Miah, Fatema Sultana Prima, Jibon Kumar Paul, ANM Shah Newaz Been Haque, Ajit Ghosh","doi":"10.1016/j.seminoncol.2025.152345","DOIUrl":"10.1016/j.seminoncol.2025.152345","url":null,"abstract":"<div><div>Cancer immunotherapy has transformed oncology by harnessing the immune system to specifically target cancer cells, offering reduced systemic toxicity compared to traditional therapies. This review highlights key strategies, including adoptive cell transfer (ACT), immune checkpoint inhibitors, oncolytic viral (OV) therapy, monoclonal antibodies (mAbs), and mRNA-based vaccines. ACT reinfuses enhanced immune cells like tumor-infiltrating lymphocytes (TILs) to combat refractory cancers, while checkpoint inhibitors (eg, PD-1 and CTLA-4 blockers) restore T-cell activity. OV therapy uses engineered viruses (eg, T-VEC) to selectively lyse cancer cells, and advanced mAbs improve targeting precision. mRNA vaccines introduce tumor-specific antigens to trigger robust immune responses. Despite significant progress, challenges like immune-related side effects, high costs, and immunosuppressive tumor microenvironments persist. This review underscores the need for combination strategies and precision medicine to overcome these barriers and maximize the potential of immunotherapy in personalized cancer treatment.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 3","pages":"Article 152345"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology and prevention of gastric cancer: A comprehensive review 胃癌的流行病学和预防：综述

IF 3 3区医学

Seminars in oncology Pub Date : 2025-06-01 Epub Date: 2025-04-29 DOI: 10.1016/j.seminoncol.2025.152341

Smruti Priyambada Pradhan , Ayushman Gadnayak , Sukanta Kumar Pradhan , Venkatarao Epari

引用次数: 0

Mechanistic role of FTO in cancer pathogenesis, immune evasion, chemotherapy resistance, and immunotherapy response FTO在癌症发病、免疫逃避、化疗耐药和免疫治疗反应中的机制作用

IF 3 3区医学

Seminars in oncology Pub Date : 2025-06-01 Epub Date: 2025-05-29 DOI: 10.1016/j.seminoncol.2025.152368

Sarah Qutayba Badraldin , Karar H. Alfarttoosi , Hayder Naji Sameer , Ashok Kumar Bishoyi , Subbulakshmi Ganesan , Aman Shankhyan , Subhashree Ray , Deepak Nathiya , Ahmed Yaseen , Zainab H. Athab , Mohaned Adil

{"title":"Mechanistic role of FTO in cancer pathogenesis, immune evasion, chemotherapy resistance, and immunotherapy response","authors":"Sarah Qutayba Badraldin , Karar H. Alfarttoosi , Hayder Naji Sameer , Ashok Kumar Bishoyi , Subbulakshmi Ganesan , Aman Shankhyan , Subhashree Ray , Deepak Nathiya , Ahmed Yaseen , Zainab H. Athab , Mohaned Adil","doi":"10.1016/j.seminoncol.2025.152368","DOIUrl":"10.1016/j.seminoncol.2025.152368","url":null,"abstract":"<div><div>Fat mass and obesity-associated protein (FTO), an N6-methyladenosine (m6A) RNA demethylase, plays a key role in cancer biology by regulating mRNA modifications. Its deregulation affects tumor cell proliferation, metastasis, immune evasion, and therapeutic resistance. By removing m6A methylation marks, FTO can alter the stability and translation of key oncogenes and tumor suppressor genes. These modifications directly influence essential cellular pathways involved in cancer progression, such as the phosphatidylinositol 3-kinases/ protein kinase B (PI3K/AKT), Wnt/β-catenin, and mammalian target of rapamycin (mTOR) signaling pathways. This review explores the mechanistic roles of FTO in cancer pathogenesis, focusing on its dual impact on immune regulation and chemotherapy response. In terms of immunity, FTO has been shown to promote immune evasion by modulating the expression of immune checkpoints and influencing the tumor microenvironment. Additionally, FTO’s influence on autophagy, glycolysis, and apoptosis resistance further complicates the effectiveness of chemotherapy treatments. By discussing the molecular details of how FTO regulates these processes, we provide insights into how FTO could serve as a promising therapeutic target to overcome cancer-related challenges, including immune resistance and chemotherapy failure. Finally, we evaluate current and emerging strategies for targeting FTO in cancer therapy, highlighting its potential to enhance immunotherapy and chemotherapy outcomes.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 3","pages":"Article 152368"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Crucial Nexus: Unveiling the Role of Collagen in Cancer Progression 关键的联系：揭示胶原蛋白在癌症进展中的作用

IF 3 3区医学

Seminars in oncology Pub Date : 2025-06-01 Epub Date: 2025-05-29 DOI: 10.1016/j.seminoncol.2025.152346

Hazel Reeva , Godson Mahesh , Uma Manjunath, Nagarajan Selvamurugan, Durairaj MohanKumar

{"title":"The Crucial Nexus: Unveiling the Role of Collagen in Cancer Progression","authors":"Hazel Reeva , Godson Mahesh , Uma Manjunath, Nagarajan Selvamurugan, Durairaj MohanKumar","doi":"10.1016/j.seminoncol.2025.152346","DOIUrl":"10.1016/j.seminoncol.2025.152346","url":null,"abstract":"<div><div>The complex interplay between collagen and cancer cells within the tumor microenvironment (TME) highlights the pivotal role of collagens in cancer progression, prognosis and therapy resistance. As a critical structural protein of the extracellular matrix (ECM), collagen not only maintains tissue architecture but also regulates key physiological functions through complex biosynthetic pathways. Deregulation in collagen biosynthesis, characterized by abnormal transcription, post-translational modifications, and deposition, contributes to ECM remodeling and tumor progression. This review explores the involvement of diverse collagen family members in cancer progression across multiple cancer types. Several collagen isoforms have emerged as key players in cancer progression, influencing tumor behavior and act as potential biomarkers for prognosis. Furthermore, circulating collagen fragments in blood present promising avenues for non-invasive cancer diagnosis and disease monitoring. Tumor collagen remodeling alters ECM architecture, impacting tumor-stromal interactions and fostering a microenvironment conducive to favour invasion and metastasis. Mechanistic insights reveal that collagen-induced signalling pathways are the major drivers of stemness, drug resistance, EMT, metastasis, angiogenesis and immune evasion, which collectively shape tumor cell behavior and immune infiltration dynamics. Further, targeting tumor collagen appear to be a viable and robust strategy to treat aggressive desmoplastic and metastatic cancers.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 3","pages":"Article 152346"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy 高肿瘤突变负荷减轻了化疗史对免疫检查点阻断治疗的负面影响

IF 3 3区医学

Seminars in oncology Pub Date : 2025-04-01 Epub Date: 2025-03-12 DOI: 10.1053/j.seminoncol.2025.01.003

Ming Zheng MD, PhD

{"title":"High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy","authors":"Ming Zheng MD, PhD","doi":"10.1053/j.seminoncol.2025.01.003","DOIUrl":"10.1053/j.seminoncol.2025.01.003","url":null,"abstract":"<div><div>Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Immune checkpoint inhibitor (ICI) therapy, particularly with PD-1 inhibitors like nivolumab, has become a critical treatment option for advanced NSCLC. ICI therapy has revolutionized treatment, but prior chemotherapy may diminish ICI treatment efficacy. Tumor mutation burden (TMB) has emerged as a crucial predictor of ICI response, yet its interaction with chemotherapy history in ICI therapy is not fully understood. In this study, I investigate the impact of chemotherapy history on ICI treatment outcomes, focusing on TMB as a potential mitigating factor. Analyzing data from 512 patients with advanced NSCLC treated with PD-1/PD-L1 or CTLA-4 inhibitors, this sudy found that prior chemotherapy significantly reduced objective response rates (ORR) to ICI therapy, particularly in patients with low TMB (<15 mut/Mb). However, in patients with high TMB (≥15 mut/Mb), the negative impact of chemotherapy history on ICI treatment efficacy is minimal, suggesting that high TMB mitigates chemotherapy-induced resistance to ICI therapy. Furthermore, while chemotherapy history is associated with worse overall survival (OS) and progression-free survival (PFS) following ICI therapy in low-TMB patients, no such association is observed in high-TMB patients. These findings highlight the importance of TMB as a predictive biomarker, emphasizing the need for optimal treatment sequencing and personalized therapeutic strategies to overcome chemotherapy-induced immune resistance and maximize ICI treatment efficacy. These results suggest that ICI therapy may be more beneficial as a first-line treatment, particularly for patients with low TMB.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 2","pages":"Article 152334"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143601473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance 综合分析scRNA-seq和大量RNA-seq数据，确定BHLHE40是胰腺癌进展和吉西他滨耐药的关键基因

IF 3 3区医学

Seminars in oncology Pub Date : 2025-04-01 Epub Date: 2025-04-17 DOI: 10.1016/j.seminoncol.2025.152338

Yang Wu , Chun Zhang , Jiacheng Huang , Qun Chen , Yufeng Zhang , Fengyuan Liu , Dong Xu , Kuirong Jiang , Run Shi , Mengxing Chen , Hao Yuan

{"title":"Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance","authors":"Yang Wu , Chun Zhang , Jiacheng Huang , Qun Chen , Yufeng Zhang , Fengyuan Liu , Dong Xu , Kuirong Jiang , Run Shi , Mengxing Chen , Hao Yuan","doi":"10.1016/j.seminoncol.2025.152338","DOIUrl":"10.1016/j.seminoncol.2025.152338","url":null,"abstract":"<div><h3>Objective</h3><div>Pancreatic cancer is characterized by its high mortality rate and short survival periods, and novel therapeutic targets and tailor personalized strategies are urgently needed. In this study, we aim to investigate the molecular mechanisms underlying pancreatic ductal adenocarcinoma (PDAC) progression and chemoresistance, with a focus on identifying novel therapeutic targets.</div></div><div><h3>Methods</h3><div>Multiomics approaches were integrated to identify novel actionable targets for PDAC. Public datasets such as TCGA and GEO were utilized to investigate the relationship between gene expression and clinical outcomes. Functional enrichment, cell-cell communication, and metabolic pathway analyses were performed to reveal PDAC heterogeneity and therapeutic resistance mechanisms.</div></div><div><h3>Results</h3><div>BHLHE40 was identified as a hub gene linked to high-CNV PDAC cells, Gemcitabine resistance, and poor prognosis in PDAC. High BHLHE40 expression is significantly correlated with immunosuppressive tumor microenvironment (TME) features such as reduced CD8+ <em>T</em> infiltration, TCR richness, and lower tumor mutational burden (TMB). ChIP-seq data analysis confirmed BHLHE40 could directly bind to the SAT1 promoter, establishing a transcriptional axis promoting chemoresistance. Single-cell RNA-seq analysis further revealed that the BHLHE40+/SAT1+ subpopulation cells are resistant to Gemcitabine in PDAC.</div></div><div><h3>Conclusions</h3><div>BHLHE40 is significantly correlated with PDAC malignancy and chemoresistance via SAT1 regulation and immune evasion. Targeting BHLHE40 may sensitize PDACs to Gemcitabine and facilitate personalized treatment for BHLHE40+ PDAC patients.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 2","pages":"Article 152338"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plant polyphenols in gastric cancer: Nature's healing touch 胃癌中的植物多酚：大自然的治愈之触

IF 3 3区医学

Seminars in oncology Pub Date : 2025-04-01 Epub Date: 2025-03-11 DOI: 10.1053/j.seminoncol.2025.01.002

Chengu Niu , Jing Zhang , Patrick I. Okolo III , Ebubekir Daglilar

{"title":"Plant polyphenols in gastric cancer: Nature's healing touch","authors":"Chengu Niu , Jing Zhang , Patrick I. Okolo III , Ebubekir Daglilar","doi":"10.1053/j.seminoncol.2025.01.002","DOIUrl":"10.1053/j.seminoncol.2025.01.002","url":null,"abstract":"<div><div>Globally, gastric cancer ranks as the fifth most common cancer and is the third most common cause of malignancy-associated mortality. Although surgery is the primary treatment option for gastric cancer, adjuvant chemotherapy improves survival in patients following surgery. Proverbially, plant polyphenols have many beneficial health effects, including anticancer properties. Extensive studies have shown that plant polyphenols exhibit potential anticancer effects against gastric cancer in vitro and in vivo, as well as very few human studies. However, this topic has not yet been reviewed. The present review shows that the potential anticancer effect of plant polyphenols on gastric cancer was preliminarily attributed to their antiproliferative, antimetastatic, and antiangiogenic effects and modulations of apoptosis, autophagy, and intracellular reactive oxygen species. Moreover, conventional therapeutics combined with plant polyphenols make gastric cancer cells more sensitive to conventional therapy. We also discuss challenges and opportunities in translating plant polyphenol-based therapy to clinical applications. The content provided in this review is of interest to pharmacologists, ethnobotanists, and oncologists who are involved in phytomedicine.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 2","pages":"Article 152333"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143592491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0